Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?

Full text
Cianni, Lorenzo [1, 2, 3] ; Feldmann, Christian Wolfgang [1] ; Gilberg, Erik [1, 2] ; Guetschow, Michael [2] ; Juliano, Luiz [4, 5] ; Leitao, Andrei [3] ; Bajorath, Juergen [1] ; Montanari, Carlos A. [3]
Total Authors: 8
[1] Rhein Friedrich Wilhelms Univ, LIMES Program Unit Chem Biol & Med Chem, B IT, Dept Life Sci Informat, Endenicher Allee 19C, D-53115 Bonn - Germany
[2] Univ Bonn, Pharmaceut Chem 1, Pharmaceut Inst, Immenburg 4, D-53121 Bonn - Germany
[3] Univ Sao Paulo, Inst Chem Sao Carlos, Med Chem Grp, Ave Trabalhador Sancarlense 400, BR-23566590 Sao Carlos, SP - Brazil
[4] Univ Fed Sao Paulo, AC Camargo Canc Ctr, Rua Prof Antonio Prudente 211, BR-01509010 Sao Paulo, SP - Brazil
[5] Univ Fed Sao Paulo, Sao Paulo Med Sch, Rua Prof Antonio Prudente 211, BR-01509010 Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Journal of Medicinal Chemistry; v. 62, n. 23, p. 10497-10525, DEC 12 2019.
Web of Science Citations: 1

Cysteine proteases are important targets for the discovery of novel therapeutics for many human diseases. From parasitic diseases to cancer, cysteine proteases follow a common mechanism, the formation of an encounter complex with subsequent nucleophilic reactivity of the catalytic cysteine thiol group toward the carbonyl carbon of a peptide bond or an electrophilic group of an inhibitor. Modulation of target enzymes occurs preferably by covalent modification, which imposes challenges in balancing cross-reactivity and selectivity. Given the resurgence of irreversible covalent inhibitors, can they impair off-target effects or are reversible covalent inhibitors a better route to selectivity? This Perspective addresses how small molecule inhibitors may achieve selectivity for different cathepsins, cruzain, rhodesain, and falcipain-2. We discuss target- and ligand-based designs emphasizing repurposing inhibitors from one cysteine protease to others. (AU)

FAPESP's process: 16/07946-5 - Synthesis and evaluation of trypanocidal activity of potential reversible covalent inhibitors of cruzain enzyme
Grantee:Lorenzo Cianni
Support type: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 13/18009-4 - Molecular design, synthesis and trypanocidal activity of cruzain reversible covalent inhibitors
Grantee:Carlos Alberto Montanari
Support type: Research Projects - Thematic Grants